Biogen Shares Rebound From Under $300 Level As Co.’s R&D Day Ongoing; Shares Up 0.9% For Session
https://biogen-r-and-d-day.videoshowcase.net/
Biogen CEO Says Working Diligently To Address Near-Term Challenges With Launch Of Alzheimer’s Drug Aduhelm
-Reuters Citing Investor Day
Biogen To Host Virtual Investor R&D Day Tuesday, Sept. 21, 2021
33 early and late-stage clinical programs across modalities and innovative discovery platforms
Uniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading
Biogen Says CHMP Recommends VUMERITY For Approval In EU As Treatment For Relapsing-Remitting Multiple Sclerosis
Biogen Inc. (NASDAQ:BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), issued a positive opinion and has recommended granting
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 16)
Expert Ratings For Biogen
Over the past 3 months, 7 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate
Biogen Inc (NASDAQ:BIIB) has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN).…
ALZN: An Elemental Approach to Alzheimer’s Disease
By John Vandermosten, CFA
NASDAQ:ALZN | NASDAQ:BIIB
UBS Maintains Buy on Biogen, Lowers Price Target to $442
UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $475 to $442.
Biogen Announces Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy; Co. Reports ‘The CONVEY study 200 mg twice daily arm met its primary endpoint while the 350 mg twice daily arm did not meet the primary endpoint’
Biogen Inc. (NASDAQ:BIIB) today announced positive topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074), a non-opioid investigational oral pain drug being evaluated for the treatment